Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Reactions
Skin
Allergic reactions
(2004): Sipos L+, Ideggyogy Sz 57(11-12), 394
Edema
(2003): Hwu W-J, J Drugs Dermatol 2, 53 (with thalidomide)
Hand–foot syndrome
(2007): Kanat O+, JPostgradMed53(2), 146
Kaposi’s sarcoma
(2006): Ganiere V+, NatClinPractOncol3(6), 339
Peripheral edema (11%)
Pruritus (8%)
Rash (sic) (8%)
(2004): Chua SL+, Neuro-oncol 6(1), 38 (14%) (with
doxorubicin)
(2003): Hwu W-J, J Drugs Dermatol 2, 53 (with thalidomide)
Hair
Hair – alopecia
(2005): Daponte A+, Anticancer Res 25(2B), 1441 (14%) (with
cisplatin)
Other
Death
(2007): Grewal J+, NEnglJMed356(15), 1591
(2007): Soetekouw PM+, Ned Tijdschr Geneeskd 151(4), 253
Fever
(2006): Ganiere V+, NatClinPractOncol3(6), 339
Hepatotoxicity
(2007): Chheda MG+, Neurology 68(12), 955 (reactivation)
Infections
(2006): Ganiere V+, NatClinPractOncol3(6), 339
(2003): Hwu W-J, J Drugs Dermatol 2, 53 (with thalidomide)
Myalgia/Myositis/Myopathy/Myotoxicity (5%)
TEMSIROLIMUS
Synonym: CC1-779
Trade name: Torisel (Wyeth)
Indications: Renal cell carcinoma, other cancers
Category: Analog of sirolimus; mTOR inhibitor
Half-life: 13–25 hours
Clinically important, potentially hazardous interactions
with: atazanavir, carbamazepine, clarithromycin, dexamethasone,
indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,
phenobarbital, phenytoin, rifabutin, rifampicin, rifampin, ritonavir,
saquinavir, St John’s wort, telithromycin, voriconazole
Reactions
Skin
Acne (10%)
(2004): Raymond E+, J Clin Oncol 22(12), 2336
Exanthems
(2005): Chan S+, J Clin Oncol 23(23), 5314 (51%)
(2004): Raymond E+, J Clin Oncol 22(12), 2336
Follicular dermatitis
(2005): Margolin K+, Cancer 104(5), 1045
Peripheral edema
(2007): Hudes G+, NEnglJMed356(22), 2271
Pruritus (19%)
(2005): Boni JP+, Clin Pharmacol Ther 77(1), 76
Rash (sic) (47%)
(2007): Hudes G+, NEnglJMed356(22), 2271
(2006): Duran I+, Br J Cancer 95(9), 1148
(2005): Chan S+, J Clin Oncol 23(23), 5314
(2005): Margolin K+, Cancer 104(5), 1045
(2004): Raymond E+, J Clin Oncol 22(12), 2336
(2003): Punt CJ+, Ann Oncol 14(6), 931
Xerosis (11%)
Mucosal
Mucositis (30%)
(2005): Chan S+, J Clin Oncol 23(23), 5314 (70%)
(2004): Raymond E+, J Clin Oncol 22(12), 2336
(2003): Punt CJ+, Ann Oncol 14(6), 931 (fatal)
Stomatitis
(2005): Chang SM+, Invest New Drugs 23(4), 357
(2005): Margolin K+, Cancer 104(5), 1045
(2004): Chang SM+, Invest New Drugs 22(4), 427
(2004): Raymond E+, J Clin Oncol 22(12), 2336
(2003): Punt CJ+, Ann Oncol 14(6), 931
Nails
Nail disorder (sic) (14%)
Eyes
Conjunctivitis (7%)
Other
Abdominal pain (21%)
Anorexia (30%)
Chills (8%)
Cough (26%)
(2006): Duran I+, Eur J Cancer 42(12), 1875
Fever (24%)
Hypersensitivity (9%)
(2006): Duran I+, Eur J Cancer 42(12), 1875
Infections (20%)
Myalgia/Myositis/Myopathy/Myotoxicity (8%)
Pain (28%)
Thrombophlebitis (1%)
Upper respiratory infection (7%)
TENECTEPLASE
Trade name: TNKase (Genentech)
Indications: Acute myocardial infarction
Category: Fibrinolytic
Half-life: 90–130 minutes
Clinically important, potentially hazardous interactions
with: bivalirudin
Reactions
Skin
Angioedema (